Brian Powl
Corporate Officer/Principal bei KURA ONCOLOGY, INC.
Vermögen: 621 962 $ am 31.03.2024
Profil
Brian T.
Powl is currently the Chief Commercial Officer at Kura Oncology, Inc. He previously worked as the Vice President-Global Commercial CAR T Lead at Celgene Corp., Senior VP-Commercial Development & Marketing at MEI Pharma, Inc., and Chief Commercial Officer at Fate Therapeutics, Inc. Powl received his undergraduate degree from the University of California San Diego and his MBA from The Wharton School of the University of Pennsylvania.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
KURA ONCOLOGY, INC.
0,02% | 02.01.2024 | 15 000 ( 0,02% ) | 319 950 $ | 31.03.2024 |
FATE THERAPEUTICS, INC.
0,04% | 05.07.2023 | 41 146 ( 0,04% ) | 302 012 $ | 31.03.2024 |
Aktive Positionen von Brian Powl
| Unternehmen | Position | Beginn |
|---|---|---|
| KURA ONCOLOGY, INC. | Corporate Officer/Principal | 14.08.2023 |
Ehemalige bekannte Positionen von Brian Powl
| Unternehmen | Position | Ende |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| MEI PHARMA, INC. | Sales & Marketing | - |
Ausbildung von Brian Powl
| University of California San Diego | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| KURA ONCOLOGY, INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
